Calidi shareholders approve reverse stock split and 3M-share equity plan increase

Calidi Biotherapeutics, Inc.

Elected James Schoeneck (6.5M for) and George Peoples (6.6M for) as Class II directors.
Ratified CBIZ CPAs P.C. as auditor for FY2025 (15.6M for, 1.3M against).
Approved reverse stock split ratio of 1:2 to 1:19, with board discretion on exact ratio.
Approved amendment to 2023 Equity Plan increasing authorized shares from 393,780 to 3,393,780.
All four proposals passed; quorum of 53.26% of shares represented.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.